Wugen, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.wugen.com
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
- Conditions
- T-cell Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT06514794
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธChildren's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธWashington University Saint Louis, Saint Louis, Missouri, United States
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
- Conditions
- Colorectal Cancer MetastaticSquamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05674526
- Locations
- ๐บ๐ธ
UCSF, San Francisco, California, United States
๐บ๐ธMontefiore Medical Center, Bronx, New York, United States
A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
- Conditions
- T-cell Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT05509855
- Locations
- ๐ฆ๐บ
Peter MacCullam Cancer Center, Melbourne, Australia
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธChildrens Hospital LA, Los Angeles, California, United States
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT05470140
- Locations
- ๐บ๐ธ
Providence Portland Medical Center, Portland, Oregon, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธUniversity of Maryland, Baltimore, Maryland, United States
A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL
- Conditions
- Lymphoblastic LymphomaT-cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Wugen, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT04984356
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐ฆ๐บPeter MacCallum Cancer Centre, Melbourne, Victoria, Australia
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States